EDAP TMS SA is convening a shareholder meeting on June 28, 2024, to approve 2023 accounts, appoint new directors, and discuss board and corporate governance, amidst announcing record revenue and growing adoption of their Focal One systems for prostate cancer treatment. The filing highlights significant clinical progress, including FDA breakthrough device designation.